Navigation Links
NEJM study points to new era in hepatitis C treatment
Date:6/5/2009

s taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 36 weeks were cured; and 61 percent of those taking telaprevir in combination with standard therapy for 12 weeks followed by standard therapy alone for 12 weeks were cured. This is compared to 41 percent cure rate in the 48-week control group.

The study also showed that the percentage of patients who relapsed in the 24-week and 48-week telaprevir-based groups (2 percent and 6 percent, respectively) was much lower than the control group (23 percent).

The most common reported side effect in the telaprevir groups was rash, and contributed to some patients discontinuing the therapy.

Peginterferon alfa-2a is an antiviral drug given by injection that is also used to treat HIV and hepatitis B; it works in conjunction with a drug called ribavirin, a nucleoside analogue, to suppress the viral activity of hepatitis C. Side effects can include severe flu-like symptoms, depression, fatigue, insomnia and anemia.

"Treating genotype 1 hepatitis C, the most common form of the infection in the United States, can be challenging because the side effects are difficult for many people to endure, the duration of treatment is long, and traditionally less than half of patients are able to be cured of their disease," says Dr. Andrew Muir, a gastroenterologist at Duke Clinical Research Institute and a senior investigator on the study. "Even though telaprevir does produce side effects of its own, its addition to standard therapy was able to improve response rates and shorten the duration of treatment necessary -- either one alone would have been an advance, and to be able to achieve both is a significant step in the right direction when it comes to treating hepatitis C."

The study's lead author is Dr. John McHutchison, a hepatologist and gastroenterologist and researcher at the Duke Clinical Research Institute. Additional co-authors include
'/>"/>

Contact: Linda Kamateh
lib9027@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... D.C. (PRWEB) , ... July 29, 2015 , ... ... released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older ... in seniors and offers recommendations on how industry, government, and health care experts ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Potomac Pilates, ... rebrand, changing its name to Rock the Reformer ® by Potomac Pilates. On ... http://www.RockTheReformer.com . Rock the Reformer ® by Potomac Pilates will continue to offer ...
(Date:7/29/2015)... ... 2015 , ... The report “Atherosclerosis - Pipeline Review, H1 ... slow, progressive disease that may start in childhood. The report strengthens R&D pipelines ... report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread ...
(Date:7/29/2015)... ... 29, 2015 , ... The healthcare analytics market is categorized ... Factors such as the rising pressure to curb healthcare costs, big data in ... capital investments are driving market growth. Check 149 data tables & 57 figures ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business on ... directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, ... the National academy of Sciences, and has given researchers inklings to explore Rsu1 in ...
Breaking Medicine News(10 mins):Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3
... slower, less efficient than the phone-free, study finds , , ... what many American drivers already knew: Drivers who talk ... conversationalists drive slower on the freeway, pass slower vehicles ... compared to the cell phone-free, reports a new study. ...
... MONTVALE, N.J., Jan. 2 Barr Pharmaceuticals,Inc. (NYSE: ... Barr Laboratories,Inc. has received final approval from the ... version of Roche Laboratories Inc.,s KYTRIL(R),(granisetron hydrochloride) Tablets, ... final approval following the expiration of Roche,s patent ...
... BEDFORD, Ohio, Jan. 3 Bedford Laboratories(TM), ... the acquisition of,CAFCIT(R) (caffeine citrate) Injection and ... & Company. Bedford Laboratories is now the,reference ... indicated for,the short term treatment of apnea ...
... Psychologists at Harvard University have developed a new method ... the century-old debate over its existence. According to the ... for studying such phenomena, but also provides the strongest ... or ESP. , The research was led by Samuel ...
... Donor Month, BETHESDA, Md., Jan. 3 AABB ... encouraging individuals,participating in the presidential elections to continue making ... throughout the month of,January, National Blood Donor Month (NBDM) ... to give blood at a time of the year ...
... Jan. 3 Hologic, Inc. (Nasdaq:,HOLX) today announced that ... Officer, will be presenting at the 26th Annual JP,Morgan ... Westin,St. Francis Hotel in San Francisco, CA., Interested ... webcast of,Hologic,s investor presentation on Wednesday, January 9, 2008 ...
Cached Medicine News:Health News:Cell Phones Put Traffic on Hold 2Health News:Cell Phones Put Traffic on Hold 3Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 3Health News:Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution 2Health News:Researchers use neuroimaging to study ESP 2Health News:Researchers use neuroimaging to study ESP 3Health News:Exercise Your Right to Vote and Continue to Make a Difference by Giving Blood in 2008 2
(Date:7/29/2015)... Calif. , July 29, 2015 /PRNewswire/ ... or the "Company"), the leading provider of ... sciences industry, serving markets including immunotherapies, stem ... manufacturers, animal health, and reproductive medicine, announced ... sale of common stock and warrants (the "Units") under ...
(Date:7/29/2015)... , July 29, 2015  Ortho-Clinical Diagnostics, Inc. (OCD) ... under development. The assays address a range of important ... and cardiac troponin I. The scientific posters will be ... Annual Meeting to be held July 26 - 30 ... "Ortho Clinical Diagnostics is emerging stronger than ever ...
(Date:7/29/2015)... July 29, 2015 The Judicial Panel on ... about whether to centralize Inferior vena cava (IVC) Filter ... manufacturer, Cook Medical, have already been centralized by the ... in patients at risk for a pulmonary embolism. The ... to the lungs. Claims against Bard and Cook involve ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3IVC filter litigation continues; law firm provides free information to IVC filter patients 2
... Infectious diseases are rampant in sub-Saharan Africa. Urbanisation ... of non-communicable diseases such as cancer. The strong ... fuelled the incidence rates of various cancers, driving ... (Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ...
... NewCardio, Inc., (OTC Bulletin Board: NWCI ... results for the second quarter ended June 30, 2010. ... the Form 10-Q, filed with the Securities and Exchange ... we have made tremendous progress in commercializing our initial ...
Cached Medicine Technology:Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan 2Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 2NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 4NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 5NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 6NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 7NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 8NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 9NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 10
Each slide contains a gram positive control of Staphylococcus aureus ATCC ® 25923 and a gram negative control of Escherichia coli ATCC ® 25922....
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
... Equalizer With 384 Well Plate Capability ... of the original Equalizerexpandable and equal tip spacing, ... in-lab calibration capabilities. In addition, this model allows ... 4.5mm for loading and accessing many gels and ...
... The Equalizer With 384 Well Plate Capability ... revolutionary features of the original Equalizerexpandable and equal ... components, and in-lab calibration capabilities. In addition, this ... down to 4.5mm for loading and accessing many ...
Medicine Products: